Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Systemic Sclerosis

An Introduction to Systemic Sclerosis

Mark CompleteCompleted
BookmarkBookmarked

touchIMMUNOLOGY coverage of EULAR 2025: The 2025 European Alliance of Associations for Rheumatology (EULAR) Congress brought together leading rheumatologists, immunologists, and allied healthcare professionals from across Europe and beyond. Running from June 11–14 in Barcelona, the conference showcased the latest advances in immune-mediated ...

Mark CompleteCompleted
BookmarkBookmarked

As part of our EULAR 2025 coverage, Dr Dinesh Khanna discusses early findings from the Breakfree-1 trial investigating BMS-986353, a next-generation CD19 CAR T-cell therapy, in severe, treatment-refractory autoimmune diseases. In this exclusive interview, Dr Khanna explores the rationale, mechanism, and encouraging early results in systemic sclerosis, highlighting robust CAR T expansion, immune reset, and meaningful clinical improvements in skin and lung outcomes.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Advances continue to be made in the treatment of systemic sclerosis (SSc, also termed ‘scleroderma’); however, it remains a challenging disease for both patients and for the clinicians caring for them. The purpose of this review is to highlight these ...

Developed by Touch
Coverage from: ACR Highlights

The SENSCIS Trial (NCT02597933) was a phase 3 randomised, double-blind, placebo controlled study, which investigated the efficacy and safety of nintedanib in the treatment of patients with systemic sclerosis associated interstitial lung disease. In this touchIMMUNOLOGY interview, it was a pleasure ...

Coverage from: ACR Highlights

It was an absolute pleasure to speak with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around the initial safety and clinical responses of patients with juvenile-onset systemic sclerosis treated with CD34...

Coverage from: ACR Highlights

In this interview, we talk with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around CD34-selected peripheral blood ASCT in patients with juvenile-onset systemic sclerosis (NCT03630211). This information is brought to ...

Coverage from: ACR Highlights

touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366). His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study ...

Load More...
Close Popup